Online Catalog
A collection of nonclinical studies & assays; customization is possible.

Interstitial Pulmonary Fibrosis (IPF) Bleomycin-Induced Lung Fibrosis

In rodents, a single intratracheal administration of Bleomycin leads to a well characterised response of 7-10 days of neutrophilic inflammation followed by a fibrotic response from around day 10 following bleomycin administration.

Currently there are only 2 approved drugs, that have been shown to slow the progression of Interstitial Pulmonary Fibrosis (IPF), nintedanib and pirfenidone.

Significant decreases in PV loops following bleomycin administration (Day 0) at Day 21, partially attenuated by therapeutic Pirfenidone Treatment 

Study Design

SD rat, C57BL/6J mouse

Model Bleomycin induced fibrosis (single intratracheal administration)
Relevant Use Assessing the efficacy of new compounds to slow the progression of IPF
Readouts Available Daily Bodyweights and Clinical Signs, Lung Function (Resistance, Compliance, PV Loops), BAL differential cell counts, Bal TGF-β, BAL cytokines, Lung Hydroxyproline, Ashcroft Scoring and Pathology

Study data generated by Labcorp Huntingdon Pharmacology.